Navigation Links
Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality

Board-Certified Regulatory Affairs Professional Brings More Than Two

Decades of Pharmaceutical, Regulatory Agency and Research Experience

CINCINNATI, Feb. 1 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the hiring of Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality. Dr. Tripathi will provide additional leadership to the Regulatory Affairs Brand, overseeing the multi-functional global regulatory group consisting of approximately 450 personnel. He will focus on driving growth in the company's regulatory brand, which includes strategic clinical development planning, regulatory consulting and submissions, clinical trial regulatory affairs, nonclinical consulting, Chemistry, Manufacturing and Controls (CMC) development, medical writing and pharmacovigilance/safety services.

(Logo: )

"We are thrilled to have someone with Satish's background and experience as part of our regulatory leadership team," said Melanie Bruno, PhD, Vice President, Global Regulatory Affairs, Quality and Safety. "His ability to analyze the regulatory complexities of drug development and fashion a market positioning strategy to help ensure commercial success will provide a wonderful resource to Kendle's customers."

Dr. Tripathi served most recently as the Director of Worldwide Regulatory Strategy at Pfizer (formerly Pharmacia). Prior to that, he was a Director of Global Regulatory Affairs at the Biosciences Division of Baxter Healthcare Corporation in charge of all global regulatory submissions within the Recombinant Strategic Business Unit. While at the U.S. Food and Drug Administration, Dr. Tripathi served as a Pharmacology and Toxicology Reviewer with an emphasis on oncology and pulmonary products.

Dr. Tripathi earned his doctorate from the University of Glasgow in Scotland, his Master of Philosophy from Bhopal University in India and bachelor's and master's degrees from Jiwaji University at Gwalior, India. His post-doctoral fellowships include the Massachusetts Institute of Technology, Emory University Medical School and the Medical College of Wisconsin.

Dr. Tripathi will be based in Kendle's Chicago office.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions -- from first-in-human studies through market launch and surveillance -- to help the world's biopharmaceutical companies maximize product life cycles and grow market share.

Our global clinical development business is focused on five regions -- North America, Europe, Asia/Pacific, Latin America and Africa -- to meet customer needs. We have conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites and named "Best CRO" for the second consecutive year by leading global pharmaceutical publication Scrip.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at

SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Present at the Wachovia 2008 Healthcare Conference
2. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
3. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
4. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
5. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
6. Kendle to Present at the UBS Global Life Sciences Conference
7. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
8. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
9. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
10. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
11. Medpace Hires Clinical Pharmacologist, Jim Wei, MD, PhD
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
(Date:11/24/2015)...  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General ... a.m. Israel time, at the law offices of ... 36 th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election ... , approval of an amendment to certain terms of options granted to ...
Breaking Biology Technology:
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
Breaking Biology News(10 mins):